Genovis AB (publ.) (STO:GENO)

Market Cap	1.12B -37.1%
Revenue (ttm)	129.65M -1.3%
Net Income	23.50M -28.6%
EPS	0.36 -29.0%
Shares Out	66.06M
PE Ratio	47.31
Forward PE	38.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,284
Average Volume	96,846
Open	17.30
Previous Close	17.30
Day's Range	16.66 - 17.50
52-Week Range	16.60 - 29.80
Beta	2.12
RSI	32.97
Earnings Date	Feb 12, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 36
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2025, Genovis AB (publ.)'s revenue was 129.65 million, a decrease of -1.27% compared to the previous year's 131.32 million. Earnings were 23.50 million, a decrease of -28.61%.